Vitamin E may protect women from the risk of venous thromboembolism, particulary those with a history of emboli or a genetic susceptibility. . .
Vitamin E may protect women from the risk of venous thromboembolism, particularly those with a history of emboli or a genetic susceptibility, according to study findings published online Sept. 10 in Circulation: Journal of the American Heart Association.
Robert J. Glynn, PhD, of Brigham and Women's Hospital in Boston, and colleagues conducted a study of 39,876 women who were randomized to receive either 600 IU of natural source vitamin E or placebo on alternate days. Blood samples were provided by 26,779 subjects to determine 2 genetic polymorphisms known to increase susceptibility to venous thromboembolism.
Over the course of a mean 10.2 years follow-up, 482 women had a venous thromboembolism, including 213 in the vitamin E group and 269 in the placebo group. For women with no previous venous thromboembolism, vitamin E supplementation conferred an 18% hazard reduction. Women with a prior venous thromboembolism had a 44% reduction, and those with a genetic susceptibility had a 49% reduction.
Glynn RJ, Ridker PM, Goldhaber SZ, et al. Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study. Circulation. 2007;116:1497-1503.
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More